

PHF8 (E6K3Y) Rabbit mAb



Orders: 877-616-CELL (2355) orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com

cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

	10^6 cells) per IP. This Application Western Blotting Immunoprecipitation Chromatin IP	s antibody has beer	se 10 µl of antibody and n validated using SimpleC			
	Western Blotting Immunoprecipitation Chromatin IP	ı		Dilution		
	Immunoprecipitation Chromatin IP	1		Dilution		
	Chromatin IP	ı	1:1000			
			1:200			
	Chromatin IP-seg	Chromatin IP		1:50		
	Chromatin IP-seq 1:50					
	Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.					
ty	PHF8 (E6K3Y) Rabbit mAb recognizes endogenous levels of total PHF8 protein.					
1	Monoclonal antibody is produced by immunizing animals with recombinant protein containing Phe579 of human PHF8 protein.					
	PHD finger protein 8 (PHF8) is a histone lysine demethylase that functions as a transcriptional activator by specifically demethylating a number of repressive histone methylation marks: mono- and di-methyl-histone H3 Lys9 (H3K9me1 and H3K9me2), di-methyl-histone H3 Lys27 (H3K27me2) and mono-methyl-histone H4 Lys20 (H4K20me1). PHF8 contains an N-terminal zinc finger-like PHD domain that binds trimethylated histone H3 Lys4 (H3K4Me3) and a C-terminal jumonji domain that is responsible for the demethylase activity (1). Deletion and point mutations (F279S) in the jumonji domain of PHF8 are associated with the onset of X-linked mental retardation (XLMR). In addition, PHF8 is highly expressed in prostate cancer, laryngeal squamous cell carcinoma, and human non-small-cell lung cancer (NSCLC). Its expression is predictive of poor survival (2-4). Overexpression of PHF8 increases cell proliferation and cell motility, while silencing of PHF8 reduces cell proliferation, migration, and invasion (4).					
nces	 Horton, J.R. et al. (2010) Nat Struct Mol Biol 17, 38-43. Zhu, G. et al. (2015) Epigenomics 7, 143-53. Shen, Y. et al. (2014) Biochem Biophys Res Commun 451, 119-25. Björkman, M. et al. (2012) Oncogene 31, 3444-56. 					
1	ces	by specifically demeth histone H3 Lys9 (H3K histone H4 Lys20 (H4 methylated histone H demethylase activity associated with the o in prostate cancer, lar Its expression is pred and cell motility, while 1. Horton, J.R. et al. (2 2. Zhu, G. et al. (2014 4. Björkman, M. et al.	by specifically demethylating a number of histone H3 Lys9 (H3K9me1 and H3K9me histone H4 Lys20 (H4K20me1). PHF8 con methylated histone H3 Lys4 (H3K4Me3) ademethylase activity (1). Deletion and po associated with the onset of X-linked me in prostate cancer, laryngeal squamous of Its expression is predictive of poor survivand cell motility, while silencing of PHF8 1. Horton, J.R. et al. (2010) Nat Struct Mo 2. Zhu, G. et al. (2015) Epigenomics 7, 14 3. Shen, Y. et al. (2014) Biochem Biophys 4. Björkman, M. et al. (2012) Oncogene 3	by specifically demethylating a number of repressive histone methistone H3 Lys9 (H3K9me1 and H3K9me2), di-methyl-histone H3 histone H4 Lys20 (H4K20me1). PHF8 contains an N-terminal zinc methylated histone H3 Lys4 (H3K4Me3) and a C-terminal jumonji demethylase activity (1). Deletion and point mutations (F279S) in associated with the onset of X-linked mental retardation (XLMR). in prostate cancer, laryngeal squamous cell carcinoma, and huma Its expression is predictive of poor survival (2-4). Overexpression and cell motility, while silencing of PHF8 reduces cell proliferation 1. Horton, J.R. et al. (2010) Nat Struct Mol Biol 17, 38-43. 2. Zhu, G. et al. (2015) Epigenomics 7, 143-53. 3. Shen, Y. et al. (2014) Biochem Biophys Res Commun 451, 119-2	by specifically demethylating a number of repressive histone methylation marks: monhistone H3 Lys9 (H3K9me1 and H3K9me2), di-methyl-histone H3 Lys27 (H3K27me2) histone H4 Lys20 (H4K20me1). PHF8 contains an N-terminal zinc finger-like PHD don methylated histone H3 Lys4 (H3K4Me3) and a C-terminal jumonji domain that is respected demethylase activity (1). Deletion and point mutations (F279S) in the jumonji domain associated with the onset of X-linked mental retardation (XLMR). In addition, PHF8 is in prostate cancer, laryngeal squamous cell carcinoma, and human non-small-cell lur. Its expression is predictive of poor survival (2-4). Overexpression of PHF8 increases cand cell motility, while silencing of PHF8 reduces cell proliferation, migration, and involved in the context of the provided Hamber of the context of the cont	

Species reactivity is determined by testing in at least one approved application (e.g., western blot).				
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.				
W: Western Blotting IP: Immunoprecipitation ChIP: Chromatin IP ChIP-seq: Chromatin IP-seq				
H: Human M: Mouse R: Rat Mk: Monkey				
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.				
SimpleChIP is a registered trademark of Cell Signaling Technology, Inc.				
XP is a registered trademark of Cell Signaling Technology, Inc.				
All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.				

Limited Uses Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's

terms and conditions that are in addition to, or different from, those contained herein, unless

separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products and trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.

Orders: 877-616-CELL (2355) • orders@cellsignal.com • Support: 877-678-TECH (8324) • info@cellsignal.com • Web: cellsignal.com For Research Use Only. Not for Use in Diagnostic Procedures.